{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:38:13Z","timestamp":1790681893828,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":43,"publisher":"Springer New York","isbn-type":[{"value":"9781493967841","type":"print"},{"value":"9781493967865","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-1-4939-6786-5_19","type":"book-chapter","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T08:45:06Z","timestamp":1483692306000},"page":"279-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Optimized Mouse Models for Liver Fibrosis"],"prefix":"10.1007","author":[{"given":"Yong Ook","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,7]]},"reference":[{"key":"19_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1055\/s-0035-1550055","volume":"35","author":"WZ Mehal","year":"2015","unstructured":"Mehal WZ, Schuppan D (2015) Antifibrotic therapies in the liver. Semin Liver Dis 35:184\u2013198","journal-title":"Semin Liver Dis"},{"key":"19_CR2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1172\/JCI66028","volume":"123","author":"D Schuppan","year":"2013","unstructured":"Schuppan D, Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123:1887\u20131901","journal-title":"J Clin Invest"},{"key":"19_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371:838\u2013851","journal-title":"Lancet"},{"key":"19_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","volume":"7","author":"SL Friedman","year":"2010","unstructured":"Friedman SL (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7:425\u2013436","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"19_CR5","doi-asserted-by":"publisher","first-page":"167sr161","DOI":"10.1126\/scitranslmed.3004700","volume":"5","author":"SL Friedman","year":"2013","unstructured":"Friedman SL, Sheppard D, Duffield JS et al (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5:167sr161","journal-title":"Sci Transl Med"},{"key":"19_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.25606","volume":"56","author":"R D\u2019ambrosio","year":"2012","unstructured":"D\u2019ambrosio R, Aghemo A, Rumi MG et al (2012) A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56:532\u2013543","journal-title":"Hepatology"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468\u2013475","journal-title":"Lancet"},{"issue":"Suppl 1","key":"19_CR8","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S0168-8278(12)60008-7","volume":"56","author":"D Schuppan","year":"2012","unstructured":"Schuppan D, Pinzani M (2012) Anti-fibrotic therapy: lost in translation? J Hepatol 56(Suppl 1):S66\u2013S74","journal-title":"J Hepatol"},{"key":"19_CR9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/hep.23123","volume":"50","author":"Y Popov","year":"2009","unstructured":"Popov Y, Schuppan D (2009) Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50:1294\u20131306","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"19_CR10","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.clinre.2015.05.005","volume":"39","author":"D Schuppan","year":"2015","unstructured":"Schuppan D (2015) Liver fibrosis: common mechanisms and antifibrotic therapies. Clin Res Hepatol Gastroenterol 39(Suppl 1):S51\u2013S59","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"19_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1755-1536-6-19","volume":"6","author":"C Liedtke","year":"2013","unstructured":"Liedtke C, Luedde T, Sauerbruch T et al (2013) Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 6:19","journal-title":"Fibrogenesis Tissue Repair"},{"key":"19_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ajpath.2014.10.013","volume":"185","author":"N Ikenaga","year":"2015","unstructured":"Ikenaga N, Liu SB, Sverdlov DY et al (2015) A new Mdr2(\u2212\/\u2212) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 185:325\u2013334","journal-title":"Am J Pathol"},{"key":"19_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","volume":"43","author":"Y Popov","year":"2005","unstructured":"Popov Y, Patsenker E, Fickert P et al (2005) Mdr2 (Abcb4)\u2212\/\u2212 mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43:1045\u20131054","journal-title":"J Hepatol"},{"key":"19_CR14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1053\/j.gastro.2011.01.040","volume":"140","author":"Y Popov","year":"2011","unstructured":"Popov Y, Sverdlov DY, Sharma AK et al (2011) Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 140:1642\u20131652","journal-title":"Gastroenterology"},{"key":"19_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/hep.27936","volume":"62","author":"C Jimenez Calvente","year":"2015","unstructured":"Jimenez Calvente C, Sehgal A, Popov Y et al (2015) Specific hepatic delivery of procollagen alpha1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology 62:1285\u20131297","journal-title":"Hepatology"},{"key":"19_CR16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","volume":"135","author":"E Patsenker","year":"2008","unstructured":"Patsenker E, Popov Y, Stickel F et al (2008) Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 135:660\u2013670","journal-title":"Gastroenterology"},{"key":"19_CR17","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/hep.23144","volume":"50","author":"E Patsenker","year":"2009","unstructured":"Patsenker E, Popov Y, Stickel F et al (2009) Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50:1501\u20131511","journal-title":"Hepatology"},{"key":"19_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","volume":"48","author":"Y Popov","year":"2008","unstructured":"Popov Y, Patsenker E, Stickel F et al (2008) Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 48:453\u2013464","journal-title":"J Hepatol"},{"key":"19_CR19","doi-asserted-by":"publisher","first-page":"G498","DOI":"10.1152\/ajpgi.00525.2011","volume":"303","author":"JM Schattenberg","year":"2012","unstructured":"Schattenberg JM, Nagel M, Kim YO et al (2012) Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 303:G498\u2013G506","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"19_CR20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64074-6","volume":"158","author":"N Sedlaczek","year":"2001","unstructured":"Sedlaczek N, Jia JD, Bauer M et al (2001) Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 158:1239\u20131244","journal-title":"Am J Pathol"},{"key":"19_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1053\/j.gastro.2014.08.038","volume":"147","author":"S Yoshida","year":"2014","unstructured":"Yoshida S, Ikenaga N, Liu SB et al (2014) Extrahepatic platelet-derived growth factor-beta, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 147:1378\u20131392","journal-title":"Gastroenterology"},{"key":"19_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1053\/gast.2002.35948","volume":"123","author":"P Fickert","year":"2002","unstructured":"Fickert P, Zollner G, Fuchsbichler A et al (2002) Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123:1238\u20131251","journal-title":"Gastroenterology"},{"key":"19_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","volume":"75","author":"JJ Smit","year":"1993","unstructured":"Smit JJ, Schinkel AH, Oude Elferink RP et al (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451\u2013462","journal-title":"Cell"},{"key":"19_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0002-9440(10)65594-0","volume":"153","author":"J Shi","year":"1998","unstructured":"Shi J, Aisaki K, Ikawa Y et al (1998) Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 153:515\u2013525","journal-title":"Am J Pathol"},{"key":"19_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1098\/rstb.1985.0169","volume":"311","author":"TF Slater","year":"1985","unstructured":"Slater TF, Cheeseman KH, Ingold KU (1985) Carbon tetrachloride toxicity as a model for studying free-radical mediated liver injury. Philos Trans R Soc Lond B Biol Sci 311:633\u2013645","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"19_CR26","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/tx3002719","volume":"25","author":"H Hajovsky","year":"2012","unstructured":"Hajovsky H, Hu G, Koen Y et al (2012) Metabolism and toxicity of thioacetamide and thioacetamide S-oxide in rat hepatocytes. Chem Res Toxicol 25:1955\u20131963","journal-title":"Chem Res Toxicol"},{"key":"19_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696\u2013699","journal-title":"J Hepatol"},{"key":"19_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gut.2005.084475","volume":"55","author":"RA Standish","year":"2006","unstructured":"Standish RA, Cholongitas E, Dhillon A et al (2006) An appraisal of the histopathological assessment of liver fibrosis. Gut 55:569\u2013578","journal-title":"Gut"},{"key":"19_CR29","doi-asserted-by":"publisher","first-page":"e11256","DOI":"10.1371\/journal.pone.0011256","volume":"5","author":"VE Meijer De","year":"2010","unstructured":"De Meijer VE, Sverdlov DY, Popov Y et al (2010) Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One 5:e11256","journal-title":"PLoS One"},{"key":"19_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1053\/j.gastro.2012.04.031","volume":"143","author":"M Kornek","year":"2012","unstructured":"Kornek M, Lynch M, Mehta SH et al (2012) Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 143:448\u2013458","journal-title":"Gastroenterology"},{"key":"19_CR31","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1074\/jbc.M600030200","volume":"281","author":"Y Popov","year":"2006","unstructured":"Popov Y, Patsenker E, Bauer M et al (2006) Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 281:15090\u201315098","journal-title":"J Biol Chem"},{"key":"19_CR32","doi-asserted-by":"publisher","first-page":"G323","DOI":"10.1152\/ajpgi.00394.2009","volume":"298","author":"Y Popov","year":"2010","unstructured":"Popov Y, Sverdlov DY, Bhaskar KR et al (2010) Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 298:G323\u2013G334","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0021-9258(19)51149-8","volume":"184","author":"RE Neuman","year":"1950","unstructured":"Neuman RE, Logan MA (1950) The determination of hydroxyproline. J Biol Chem 184:299\u2013306","journal-title":"J Biol Chem"},{"key":"19_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2008-1040452","volume":"10","author":"D Schuppan","year":"1990","unstructured":"Schuppan D (1990) Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 10:1\u201310","journal-title":"Semin Liver Dis"},{"key":"19_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-2001-17556","volume":"21","author":"D Schuppan","year":"2001","unstructured":"Schuppan D, Ruehl M, Somasundaram R et al (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351\u2013372","journal-title":"Semin Liver Dis"},{"key":"19_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0003-2697(60)90050-6","volume":"1","author":"DJ Prockop","year":"1960","unstructured":"Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228\u2013239","journal-title":"Anal Biochem"},{"key":"19_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/hep.510260316","volume":"26","author":"G Boigk","year":"1997","unstructured":"Boigk G, Stroedter L, Herbst H et al (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643\u2013649","journal-title":"Hepatology"},{"key":"19_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0016-5085(00)70370-2","volume":"118","author":"JJ Cho","year":"2000","unstructured":"Cho JJ, Hocher B, Herbst H et al (2000) An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 118:1169\u20131178","journal-title":"Gastroenterology"},{"key":"19_CR39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1056\/NEJM199705293362217","volume":"336","author":"B Gerling","year":"1997","unstructured":"Gerling B, Becker M, Staab D et al (1997) Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med 336:1611\u20131612","journal-title":"N Engl J Med"},{"key":"19_CR40","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1152\/ajplung.2001.280.1.L39","volume":"280","author":"M Fujita","year":"2001","unstructured":"Fujita M, Shannon JM, Irvin CG et al (2001) Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 280:L39\u2013L49","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"19_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LC Junqueira","year":"1979","unstructured":"Junqueira LC, Bignolas G, Brentani RR (1979) Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 11:447\u2013455","journal-title":"Histochem J"},{"key":"19_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF00788278","volume":"89","author":"P Whittaker","year":"1994","unstructured":"Whittaker P, Kloner RA, Boughner DR et al (1994) Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89:397\u2013410","journal-title":"Basic Res Cardiol"},{"key":"19_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.1840010511","volume":"1","author":"RG Knodell","year":"1981","unstructured":"Knodell RG, Ishak KG, Black WC et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431\u2013435","journal-title":"Hepatology"}],"container-title":["Methods in Molecular Biology","Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-6786-5_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:28:07Z","timestamp":1658352487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-6786-5_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9781493967841","9781493967865"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-6786-5_19","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"7 January 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}